Shanghai Pharmaceuticals Holding Co., Ltd. — Proxy Solicitation & Information Statement 2025

Mar 12, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SPH 上海医药
SHANGHAI PHARMA

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02607)

SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR, NOTICE OF EXTRAORDINARY GENERAL MEETING AND PROXY FORM OF HOLDERS OF H SHARES FOR USE AT EXTRAORDINARY GENERAL MEETING TO BE HELD ON 13 MARCH 2025

References are made to the announcement dated 11 January 2025 (the "Announcement"), the circular (the "Circular") and notice (the "Notice") of extraordinary general meeting and the proxy form of holders of H shares (the "Proxy Form") for use at extraordinary general meeting to be held on 13 March 2025 (the "EGM") dated 21 February 2025 of Shanghai Pharmaceuticals Holding Co., Ltd. (the "Company"), respectively. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company noted that the spelling of the English name of Dr. WAN Jun (萬鈞博士), a candidate of the independent non-executive Director of the eighth session of the Board, as set out on pages 1 to 2 of the English version of the Announcement, pages 5 to 6 of the English version of the Circular and the Resolution 2.01 under the English version of the Proxy Form was a direct translation from her Chinese name “萬鈞”. The Company would like to further clarify that the official English legal name of 萬鈞 shall be read as below:

"Dr. WAN Jun MAN Kwan"

For the avoidance of doubt, the Chinese name of Dr. MAN Kwan, 萬鈞, as set out in the Chinese versions of the Announcement, the Circular and the Proxy Form, is accurate and remains unchanged. Save as disclosed above, all other information and contents stated in the Announcement, the Circular, the Notice and the Proxy Form (both English and Chinese versions) shall remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement, the Circular, the Notice and the Proxy Form.

The English version of the Proxy Form in the form as it is now will remain valid for use for the EGM or any adjournment thereof. For the avoidance of doubt, the English version of the Proxy Forms lodged by the Shareholders prior to the date hereof shall continue to be valid to the fullest extent applicable, if correctly completed. In the event that the Shareholders voted "Agree" for the Resolution 2.01 in the original English version of the Proxy Form, they will be deemed to have voted "Agree" for the revised Resolution 2.01.

---

By order of the Board

Shanghai Pharmaceuticals Holding Co., Ltd.*

YANG Qiuhua

Chairman

Shanghai, the PRC, 12 March 2025

As of the date of this announcement, the executive Directors of the Company are Mr. YANG Qiuhua, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Director is Mr. ZHANG Wenxue; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. FOK Manson and Mr. WANG Zhong.

• For identification purpose only